Introduction: Mammography is the gold standard for early breast cancer detection, but shows important limitations. Blood-based approaches on basis of cell-free DNA (cfDNA) provide minimally invasive screening tools to characterize epigenetic alterations of tumor suppressor genes and could serve as a liquid biopsy, complementing mammography.
Methods: Potential biomarkers were identified from The Cancer Genome Atlas (TCGA), using HumanMethylation450-BeadChip data. Promoter methylation status was evaluated quantitatively by pyrosequencing in a serum test cohort ( 103), a serum validation cohort ( 368) and a plasma cohort ( 125).
Results: , and were identified as novel biomarker candidates. was included on basis of our previous work. In the serum test cohort, a panel of and showed 63% sensitivity for DCIS and 51% sensitivity for early invasive tumor (pT1, pN0) detection at 80% specificity. The serum validation cohort revealed 50% sensitivity for DCIS detection on basis of and . Furthermore, an inverse correlation between methylation frequency and cfDNA concentration was uncovered. Therefore, markers were tested in a plasma cohort, achieving a 64% sensitivity for breast cancer detection using , and .
Conclusions: Although liquid biopsy remains challenging, a combination of , , and (SNiPER) provides a promising tool for blood-based breast cancer detection.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849652 | PMC |
http://dx.doi.org/10.18632/oncotarget.27303 | DOI Listing |
East Mediterr Health J
December 2024
Department of Radiology, King Abdulaziz University, Jeddah, Saudi Arabia.
Background: Breast cancer is often thought to occur at a younger age among Arab women based on the mean or median age at diagnosis, or the proportion of women diagnosed with breast cancer at a young age.
Objective: To compare age-specific breast cancer incidence rates among women from selected Arab countries with selected high- and middle-income countries.
Methods: We examined population-based, age-specific, national or regional breast cancer incidence data for 2008-2012 and 2013-2017 from Australia, Brazil, Canada, Germany, Japan, United Kingdom, and United States of America, and compared them with data from Algeria, Bahrain, Jordan, Kuwait, Morocco, Qatar, and Saudi Arabia.
Pharm Dev Technol
January 2025
Department of Pharmacy, School of Chemistry and Chemical Engineering, Liaoning Normal University, Dalian 116029, China.
In this paper, the pH-sensitive targeting functional material NGR-poly(2-ethyl-2-oxazoline)-cholesteryl methyl carbonate (NGR-PEtOz-CHMC, NPC) modified quercetin (QUE) liposomes (NPC-QUE-L) was constructed. The structure of NPC was confirmed by infrared spectroscopy (IR) and nuclear magnetic resonance hydrogen spectrum (H-NMR). Pharmacokinetic results showed that the accumulation of QUE in plasma of the NPC-QUE-L group was 1.
View Article and Find Full Text PDFJ Med Econ
January 2025
UNESCO-TWAS, The World Academy of Sciences, Trieste, Italy.
Aim: Dynamic cancer control is a current health system priority, yet methods for achieving it are lacking. This study aims to review the application of system dynamics modeling (SDM) on cancer control and evaluate the research quality.
Methods: Articles were searched in PubMed, Web of Science, and Scopus from the inception of the study to November 15th, 2023.
Int J Surg
January 2025
Computer Science and Technology, Harbin Institute of Technology (Shenzhen), Shenzhen, China.
Detection of biomarkers of breast cancer incurs additional costs and tissue burden. We propose a deep learning-based algorithm (BBMIL) to predict classical biomarkers, immunotherapy-associated gene signatures, and prognosis-associated subtypes directly from hematoxylin and eosin stained histopathology images. BBMIL showed the best performance among comparative algorithms on the prediction of classical biomarkers, immunotherapy related gene signatures, and subtypes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!